Evenity (Romosozumab) and Testosterone Interaction

Why This Combination Comes Up in Clinical Practice

Men with osteoporosis frequently have concurrent hypogonadism. Up to 20% of men with osteoporotic vertebral fractures have testosterone levels below 300 ng/dL, according to data reviewed by the Endocrine Society's 2018 clinical practice guideline on testosterone therapy [1]. When bone loss is severe enough to warrant romosozumab, the prescribing clinician often faces a patient already receiving testosterone replacement therapy (TRT).

Why Both Drugs Target Bone Differently

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that suppresses bone formation. Blocking sclerostin both stimulates osteoblast activity and, to a lesser degree, reduces osteoclast-mediated resorption [2]. Testosterone supports bone through a separate pathway: aromatization to estradiol in peripheral tissues, which reduces bone resorption, plus direct androgen-receptor-mediated effects on periosteal apposition [3].

No Shared Metabolic Pathway

Because romosozumab is a large-molecule biologic cleared by the reticuloendothelial system and testosterone is metabolized primarily by hepatic CYP3A4 and 5-alpha-reductase, the two drugs share no metabolic enzymes, no transporter competition (P-glycoprotein, OATP), and no protein-binding displacement. The interaction between them is entirely pharmacodynamic.

The Cardiovascular Overlap: The Core Safety Concern

The FDA-approved prescribing information for Evenity carries a boxed warning for major adverse cardiovascular events (MACE) [4]. In the ARCH trial (N=4,093), romosozumab-treated patients had a higher incidence of adjudicated cardiovascular events (2.5%) compared to alendronate-treated controls (1.9%) within the first 12 months of therapy [5].

Testosterone's Separate CV Signal

Testosterone therapy adds its own cardiovascular question marks. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found no statistically significant increase in MACE with transdermal testosterone versus placebo in men aged 45 to 80 with pre-existing or high risk for cardiovascular disease (HR 0.99; 95% CI 0.81 to 1.21) [6]. That trial was reassuring but did not study men simultaneously taking romosozumab.

Additive Risk in Theory

No clinical trial has directly evaluated the co-administration of romosozumab and testosterone. The concern is theoretical but grounded: if a patient already carries baseline cardiovascular risk factors (hypertension, dyslipidemia, diabetes), layering a drug with a MACE boxed warning on top of exogenous androgen therapy warrants closer surveillance. The 2020 AACE/ACE guidelines for postmenopausal osteoporosis (which inform male osteoporosis management by analogy) recommend avoiding romosozumab in patients with recent MI or stroke within the prior year [7].

Polycythemia: The Hematologic Risk That Compounds

Testosterone stimulates erythropoietin production and acts directly on erythroid progenitor cells in bone marrow. Polycythemia (hematocrit >54%) is the most common adverse effect of TRT, occurring in 3 to 18% of men depending on formulation and dose [1]. Injectable testosterone cypionate and enanthate produce supratherapeutic peaks that carry higher polycythemia rates than transdermal gels [8].

How Romosozumab Fits In

Romosozumab itself does not cause polycythemia. It does not affect erythropoiesis. The concern is indirect: elevated hematocrit increases blood viscosity, which raises the risk of thromboembolic events. In a patient already flagged for cardiovascular vigilance because of romosozumab's boxed warning, an unchecked hematocrit climbing above 54% could compound thromboembolic risk.

The Monitoring Protocol

The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months after starting TRT, and then annually [1]. When romosozumab is added to an existing TRT regimen, many clinicians tighten this schedule to every 3 months for the 12-month romosozumab treatment window. If hematocrit exceeds 54%, options include reducing the testosterone dose, switching from injectable to transdermal delivery, or therapeutic phlebotomy.

Lipid Effects: Monitoring Both Contributions

Testosterone replacement typically lowers HDL cholesterol by 5 to 10%, an effect documented across multiple formulations in a meta-analysis published in the Journal of Clinical Endocrinology & Metabolism [9]. Exogenous testosterone may also modestly reduce total cholesterol and LDL, but the HDL suppression is the most clinically relevant shift. Romosozumab has not been associated with direct lipid changes in its clinical trial program [4] [5].

Why Lipids Still Matter During Co-Treatment

The cardiovascular boxed warning on romosozumab means that any worsening of a modifiable CV risk factor (including dyslipidemia from TRT) takes on added clinical weight during the 12-month treatment course. A fasting lipid panel at baseline and at 6 months is reasonable. If HDL drops below 40 mg/dL on TRT, consider dose adjustment or statin initiation per ACC/AHA lipid guidelines [10].

Blood Pressure Considerations

Testosterone can cause fluid retention, which may raise blood pressure in susceptible patients. Romosozumab's package insert lists hypertension as part of the cardiovascular concern cluster [4]. Blood pressure should be checked at each TRT follow-up and at each romosozumab injection visit (monthly).

Bone Density Outcomes: Does the Combination Help More?

No randomized trial has compared romosozumab plus testosterone versus either agent alone in hypogonadal men with osteoporosis. The available evidence comes from separate trial programs.

Romosozumab Alone

In the FRAME trial (N=7,180), romosozumab 210 mg monthly for 12 months increased lumbar spine BMD by 13.3% versus 0.0% with placebo, with a 73% reduction in new vertebral fractures at 12 months [11]. The ARCH trial showed that romosozumab followed by alendronate reduced fracture risk more effectively than alendronate alone [5].

Testosterone Alone

A meta-analysis of 8 RCTs in hypogonadal men found that testosterone therapy increased lumbar spine BMD by a weighted mean of 3.7% over 12 months [12]. The effect on fracture reduction is less well-established. The Endocrine Society notes that testosterone alone should not be considered adequate therapy for men with severe osteoporosis or prevalent fragility fractures [1].

Theoretical Additive Benefit

Because romosozumab primarily stimulates bone formation (anabolic) while testosterone reduces resorption (antiresorptive, via estradiol), the two agents target complementary arms of bone remodeling. Dual-mechanism coverage could theoretically produce greater BMD gains, though this remains unconfirmed in clinical trials. Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University, has noted: "Combining an anabolic agent with antiresorptive therapy, whether hormonal or pharmacologic, has a strong mechanistic rationale in patients with very high fracture risk" [13].

Practical Prescribing: Timing, Sequence, and Duration

Romosozumab is administered as two subcutaneous injections of 105 mg each (total 210 mg) once monthly for 12 consecutive months. It should not be repeated [4]. Testosterone replacement, by contrast, is ongoing.

Starting Romosozumab in a Patient Already on TRT

No dose modification of testosterone is required. Confirm the following before the first romosozumab injection:

• Hematocrit is <50% (ideally <48%)
• Blood pressure is <140/90 mmHg
• No MI or stroke within the prior 12 months
• Serum calcium and 25-hydroxyvitamin D are within normal limits

Starting TRT in a Patient Already on Romosozumab

If testosterone is being initiated during an active romosozumab course, transdermal formulations (gels, patches) are preferred over injectables to minimize hematocrit spikes during the cardiovascular surveillance window. Start with the lowest effective dose and recheck hematocrit at 6 weeks.

After the Romosozumab Course

Once the 12-month romosozumab course ends, transition to a follow-on antiresorptive (typically a bisphosphonate or denosumab) to preserve BMD gains [7]. Testosterone continuation at this stage carries the same standard TRT monitoring, without the added urgency of the romosozumab cardiovascular signal.

Who Should Avoid This Combination

The combination is contraindicated when a patient has had a myocardial infarction or stroke within the past 12 months [4]. Relative contraindications include uncontrolled hypertension, hematocrit >50% at baseline, untreated polycythemia vera, or active congestive heart failure (NYHA class III/IV).

The American Association of Clinical Endocrinology (AACE) recommends that the cardiovascular risk/benefit ratio be discussed explicitly with the patient before starting romosozumab, especially in men who may carry androgen-related CV risk factors [7].

Monitoring Schedule for Co-Treatment

| Test | Baseline | Month 3 | Month 6 | Month 12 | |---|---|---|---|---| | Hematocrit / CBC | Yes | Yes | Yes | Yes | | Lipid panel | Yes | | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | | Serum calcium | Yes | | Yes | | | 25-OH vitamin D | Yes | | | Yes | | PSA (men >40) | Yes | | Yes | | | DXA scan | Yes (if not recent) | | | Yes |

Monthly blood pressure checks at each romosozumab injection visit are practical and add no extra appointments. Hematocrit checks at months 3, 6, and 12 exceed the Endocrine Society minimum but align with the heightened cardiovascular surveillance warranted by romosozumab's boxed warning.

Patient Counseling Points

Patients should report chest pain, sudden shortness of breath, unilateral leg swelling, or new-onset severe headache immediately. These symptoms could indicate a cardiovascular or thromboembolic event, and prompt evaluation is required. Advise patients not to skip monthly romosozumab injections, as interrupted dosing has not been studied and could compromise the time-limited anabolic window. Men on injectable testosterone should report injection-day flushing or headaches, which could signal hematocrit-related hyperviscosity. A hematocrit drawn 1 week after an injection peak (typically day 3 to 5 post-injection for cypionate) captures near-peak erythrocyte stimulation and is the most informative timing for safety monitoring [1].